Author Archive for: ANevill

About ANevill

This author has yet to write their bio.
Meanwhile lets just say that we are proud ANevill contributed a whooping 38 entries.

Entries by

Advent Life Sciences Announces Close of Two New Funds Totalling $215 million

18 February 2021 in Advent Life Sciences, Client news, Uncategorised /by ANevill

Read full release

Anticancer Bioscience Announces CNY63m (~USD10m) Financing to Advance its Synthetic Lethal Platform and Pre-clinical Oncology Pipeline

8 February 2021 in Anticancer Bioscience, Client news /by ANevill

Read full release

The Key to Playing Harmoniously at BIO-Europe Spring® Digital 2021

8 February 2021 in News /by ANevill

Can it really be almost a whole year since BIO-Europe Spring® 2020 went digital? In Groundhog Day, Bill Murray had become a concert pianist by this point in the film, having relived the same day several hundred times over, but wisely spending a little time each day to practice the piano, so he could successfully […]

Vaccitech Doses First Patient in HBV002, a Phase 1b/2a Clinical Trial of VTP-300 Immunotherapeutic Candidate for Chronic HBV Patients

1 February 2021 in Client news, Vaccitech /by ANevill

Read full release

X-Bolt Features in Largest Ever Hip Fracture Fixation Trial Publication

1 February 2021 in Client news /by ANevill

Read full release

BC Platforms, RIKEN and the Finnish Institute for Health and Welfare (THL) collaborate on artificial intelligence approach to identify people most at risk of from COVID-19

26 January 2021 in BC Platforms, Client news, Uncategorised /by ANevill

Read full release

Pneumagen Announces £2.5m fundraising to advance universal treatment for viral respiratory infections into the clinic this year

21 January 2021 in Client news, Pneumagen /by ANevill

Read full release

InVixa announces licensing deal with University of California, Davis for the commercialization of novel inhaled statins for the treatment of COVID-19

19 January 2021 in Client news, InVixa /by ANevill

Read full release